We also demonstrated that median FGA is significantly lower in patients with BRAF alteration of a known functional class compared to unselected NSCLC, but this difference is probably driven by the lower median FGA in patients with class 1 alterations. This evidence concerns the gene BRAF and non-small cell lung carcinoma.